Methods for treating neurological disorders

Abstract

Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.

1 .- 17 . (canceled) 
     
     
         18 . A method of selecting and treating a patient suffering from Alzheimer's disease comprising the steps of:
 (a) selecting the patient as having a tramiprosate-sensitive form of Alzheimer's disease based on the presence of one or more ApoE4 alleles; and   (b) administering to the selected patient tramiprosate in an amount effective to treat the disease.   
     
     
         19 . The method of  claim 18 , wherein the administration of the compound to the patient is for a period of greater than 13 weeks. 
     
     
         20 . A method of selecting and treating a patient suffering from Alzheimer's disease comprising the steps of:
 (a) selecting the patient as having a tramiprosate-sensitive form of Alzheimer's disease based on the presence of one or more ApoE4 alleles; and   (b) administering to the selected patient a compound having the formula:   
       
         
           
           
               
               
           
         
         in an amount effective to treat the disease. 
       
     
     
         21 . The method of  claim 18 , wherein the treatment reduces cognitive decline in the patient. 
     
     
         22 . The method of  claim 20 , wherein the treatment reduces cognitive decline in the patient. 
     
     
         23 . The method of  claim 18 , wherein the compound is administered in an oral dosage form. 
     
     
         24 . The method of  claim 23 , wherein the dosage range is between about 100 mg to about 150 mg. 
     
     
         25 . The method of  claim 20 , wherein the administration of the compound to the patient is for a period of greater than 13 weeks. 
     
     
         26 . The method of  claim 20 , wherein the compound is administered in an oral dosage form. 
     
     
         27 . The method of  claim 26 , wherein the dosage range is between about 150 mg to about 300 mg. 
     
     
         28 . The method of  claim 23 , wherein the compound is administered twice daily. 
     
     
         29 . The method of  claim 24 , wherein the compound is administered twice daily. 
     
     
         30 . The method of  claim 26 , wherein the compound is administered twice daily. 
     
     
         31 . The method of  claim 27 , wherein the compound is administered twice daily. 
     
     
         32 . The method of  claim 18 , wherein the patient is selected on the basis of having one copy of the ApoE4 allele. 
     
     
         33 . The method of  claim 20 , wherein the patient is selected on the basis of having one copy of the ApoE4 allele.